{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"44.5","value":"12.5"},{"comment":"A confidence interval cannot be computed when the rate is zero, i.e. when there are zero events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG002","lowerLimit":"2.1","upperLimit":"37.7","value":"14.3"},{"groupId":"OG003","lowerLimit":"3.3","upperLimit":"22.9","value":"10.6"},{"groupId":"OG004","lowerLimit":"3.8","upperLimit":"26.1","value":"12.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"33"}],"units":"Participants"}],"description":"Local progression is the same as primary tumor failure (PTF) which refers to the primary treated tumor after protocol therapy and corresponds to meeting both of the following two criteria: 1) Increase in tumor dimension of 20% as defined above for local enlargement (LE); 2) The measurable tumor with criteria meeting LE should be avid on Positron Emission Tomography (PET) imaging with uptake of a similar intensity as the pretreatment staging PET, OR the measurable tumor should be biopsied confirming viable carcinoma. For outcome analysis, Marginal Failures (MF) and Involved Lobe Failures will also be counted as PTF. Local progression was assessed using the cumulative incidence method to estimate the 2-year failure rate. Arms were not compared/tested.","dispersionType":"95% Confidence Interval","groups":[{"description":"SBRT delivered in 5 fractions of 10.0 Gy/fraction over 1.5 to 2 weeks for a total of 50.0 Gy","id":"OG000","title":"Level 5: 10.0 Gy/FX"},{"description":"SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy","id":"OG001","title":"Level 6: 10.5 Gy/FX"},{"description":"SBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy","id":"OG002","title":"Level 7: 11.0 Gy/FX"},{"description":"SBRT 57.5 Gy\n\nSBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy","id":"OG003","title":"Level 8: 11.5 Gy/FX"},{"description":"SBRT 60.0 Gy\n\nSBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy","id":"OG004","title":"Level 9: 12.0 Gy/FX"}],"paramType":"NUMBER","populationDescription":"All eligible patients who started study treatment","reportingStatus":"POSTED","timeFrame":"From randomization to date of death, regional failure or last follow-up. Analysis occurs after all patients have been potentially followed for 24 months.","title":"Local Progression","type":"SECONDARY","unitOfMeasure":"percentage of participants"}